David G. Waters

Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide

Sophie Callies, Valérie André, Bharvin K.R. Patel et al. · British Journal of Clinical Pharmacology · 2010 · 29 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects.

Suzanne Knapp, M.L. Wardlow, Kenneth S. Albert et al. · Drug Metabolism and Disposition · 1991 · 27 citations

Medicine, Pharmacokinetics, Pharmacology +14

Determination of residual solvent levels in bulk pharmaceuticals by capillary gas chromatography

Ian D. Smith, David G. Waters · The Analyst · 1991 · 25 citations

Pharmacy, Pharmaceutical Analysis, Analytical Chemistry +16

Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys

David O. Clarke, Kim G. Hilbish, David G. Waters et al. · Reproductive Toxicology · 2015 · 21 citations

Life Sciences, Immunology, Pharmacology +17

A Radioimmunoassay for LY315902 an analog of Glucagon-like Insulinotropic Peptide, and Its Application in the Study of Canine Pharmacokinetics

James Chou, G D Place, David G. Waters et al. · Journal of Pharmaceutical Sciences · 1997 · 19 citations

Medicine, Endocrinology, Pharmacokinetics +3